Cement G received FDA authorization earlier in 2022, according to an Oct. 24 company news release. It addresses the site of infection with a single-stage surgical approach. A clinical study found Cerament G reduces the risk of bone infection to 4.3 to 5.5 percent compared to 13.3 percent with standard care.
Cerament G is the first FDA approved combination antibiotic-eluting bone graft. Dr. Conway is head of bone and joint infection at Sinai Hospital of Baltimore.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.